

Research Ethics Committee Reference Number	IRAS Number	Name of Trial	Target Number Of Patients Agreed?	Minimum Number Of Patients Agreed	Maximum Number Of Patients Agreed	Target date to recruit patients agreed	Date Agreed to recruit target number of patients	Total Number Of Patients Recruited At The Agreed Target Date	Date That The Trial Closed To Recruitment	Total Number Of Study Participants Recruited	Reason For Closure Of Trial	Comments
17/ES/0032	212775	DSP-DE-MS-14-009: Global Liquid biopsy study in NSCLC	Number Agreed	20	30	Date Agreed	01/10/2018	19	03/07/2018	19	Recruitment Finished	Study recruitment target extended at Sponsor request, then Sponsor closed the study early.
17/EE/0177	220722	BOSTON: A phase 3 randomized, controlled, open-label study of selinexor, bortezomib, and dexamethasone (SVD) versus bortezomib and dexamethasone (VD) in patients with Relapsed or Refractory Multiple Myeloma (RRMM)	Number Agreed	3	3	Date Agreed	01/12/2018	0	27/09/2018	0	Recruitment Finished	Rare Patient Group & study closed to recruitment earlier than expected.
11/LO/2019	76882	TOPARP: Phase II Trial of Olaparib in Patients with Advanced Castration Resistant Prostate Cancer	Number Agreed	3	3	Date Agreed	19/06/2018	6	19/06/2018	6	Recruitment Finished	Target exceeded
17/SC/0231	221097	PROMISE-MESO: A multicentre randomised phase III trial comparing pembrolizumab versus standard chemotherapy for advanced pre-treated malignant pleural mesothelioma	Number Agreed	15	15	Date Agreed	31/10/2020	12	14/08/2018	12	Recruitment Finished	Sponsor closed recruitment earlier than expected
14/LO/1672	158949	Polo - A Phase III, Randomised, Double Blind, Placebo Controlled, Multicentre Study of Maintenance Olaparib Monotherapy in Patients with gBRCA Mutated Metastatic Pancreatic Cancer whose Disease Has Not Progressed on First Line Platinum Based Chemothe	Number Agreed	2	2	Date Agreed	31/07/2019	1	15/08/2018	1	Recruitment Finished	Sponsor closed recruitment earlier than expected: very rare patient group
17/LO/1652	233586	CA209-9TW: RETROSPECTIVE CHART REVIEW STUDY OF FIRST-LINE TREATMENT PATTERNS AND CLINICAL OUTCOMES IN PATIENTS WITH ADVANCED (UNRESECTABLE OR METASTATIC) MELANOMA IN THE UNITED KINGDOM	Number Agreed	50	50	Date Agreed	31/08/2018	56	31/08/2018	56	Recruitment Finished	Target exceeded
17/NW/0312	211974	CaboGIST (EORTC 1317): Phase II study of cabozantinib in patients with metastatic gastrointestinal stromal tumor (GIST) who progressed during neoadjuvant, adjuvant or palliative therapy with imatinib and sunitinib.	Number Agreed	3	3	Date Agreed	31/12/2019	1	31/08/2018	1	Recruitment Finished	Sponsor closed recruitment earlier than expected
16/LO/1514	200096	KEYNOTE 240: A Phase III Study of Pembrolizumab (MK-3475) vs. Best Supportive Care as Second-Line Therapy in Subjects with Previously Systemically Treated Advanced Hepatocellular Carcinoma (KEYNOTE-240)	Number Agreed	3	3	Date Agreed	01/02/2019	2	19/09/2018	2	Recruitment Finished	Sponsor closed recruitment earlier than expected
16/NW/0130	196702	LUME BIONIS: A non-interventional biomarker study in patients with Non-Small Cell Lung Cancers (NSCLCs) of adenocarcinoma tumour histology treated in second line with nintedanib in combination with docetaxel	Number Agreed	5	5	Date Agreed	15/04/2020	0	30/10/2018	0	Withdrawn By Sponsor	Sponsor discontinued study after requesting an extension to recruitment numbers
15/LO/0159	169996	SELPAC Uveal Melanoma Study	Number Agreed	15	15	Date Agreed	28/11/2018	17	28/11/2018	17	Recruitment Finished	Target exceeded